Search - tctmd.com

Displaying 41 - 60 of 66

Sort: Relevancy | Date

Presentation TCT 2015

Intravenous P2Y12 Inhibition: Role for Cangrelor

Presenter: George D. Dangas, Paul A. Gurbel, Robert A. Harrington

October 13, 2015

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Cangrelor!

Presenter: Eric Boersma, E. Magnus Ohman, Deepak L. Bhatt

October 12, 2015

Presentation TCT 2015

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

Presenter: John A. Bittl, Robert A. Harrington, Harvey D. White

October 12, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Presenter: C. Michael Gibson, Marco Valgimigli, Sigmund Silber

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Presenter: C. Michael Gibson, Marco Valgimigli, Guido Parodi

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

Presenter: C. Michael Gibson, Marco Valgimigli, Harvey D. White

October 11, 2015

Presentation

CHAMPION PHOENIX: Effect of Cangrelor and Access Site on Ischemic and Bleeding Events

Presenter: JA. Gutierrez

October 05, 2015

Presentation TCT 2014

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Presenter: John M. Lasala, Stuart J. Pocock, Deepak L. Bhatt

September 16, 2014

Presentation TCT 2014

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Presenter: Deepak Bhatt

September 16, 2014

Presentation TCT 2014

Definitely To Prevent Stent Thrombosis and MI!

Presenter: Gregg W. Stone

September 15, 2014

Presentation TCT 2014

Definitely Not An Expensive Way to Increase Bleeding Without Much Benefit!

Presenter: Nick Curzen

September 15, 2014

Presentation TCT 2014

Cangrelor III: Detailed Effects on Intraprocedural and Postprocedural Stent Thrombosis

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux

September 15, 2014

Presentation TCT 2014

Cangrelor II: New Data from the FDA Advisory Board Panel

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux, Robert A. Harrington

September 15, 2014

Presentation TCT 2014

Cangrelor I: Data Essentials from the Champion Trials

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux, Deepak L. Bhatt

September 15, 2014

Presentation TCT 2014

NO: Cangrelor Is No Champion Next to the Appropriate Use of Potent Oral Antiplatelet Agents!

Presenter: Dimitrios Alexopoulos

September 14, 2014

Presentation

Incidence and Impact of Stent Thrombosis after PCI: Comparison of Cangrelor and Clopidogrel

Presenter: Philippe Généreux

April 02, 2014

Presentation ACC 2014

Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial

Presenter: Philippe Généreux

March 30, 2014

Presentation TCT 2013

I'm Sure: Cangrelor Is Required In Addition!

Presenter: Gregg Stone

October 31, 2013

Presentation TCT 2013

Cangrelor Will Be the Answer for Most in the Acute Setting!

Presenter: Robert Harrington

October 31, 2013

Presentation TCT 2013

Cangrelor Properties: PK, PD and More

Presenter: Sergio Leonardi

October 31, 2013

Advertisement

Intravenous P2Y12 Inhibition: Role for Cangrelor

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Cangrelor!

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

CHAMPION PHOENIX: Effect of Cangrelor and Access Site on Ischemic and Bleeding Events

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Definitely To Prevent Stent Thrombosis and MI!

Definitely Not An Expensive Way to Increase Bleeding Without Much Benefit!

Cangrelor III: Detailed Effects on Intraprocedural and Postprocedural Stent Thrombosis

Cangrelor II: New Data from the FDA Advisory Board Panel

Cangrelor I: Data Essentials from the Champion Trials

NO: Cangrelor Is No Champion Next to the Appropriate Use of Potent Oral Antiplatelet Agents!

Incidence and Impact of Stent Thrombosis after PCI: Comparison of Cangrelor and Clopidogrel

Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial

I'm Sure: Cangrelor Is Required In Addition!

Cangrelor Will Be the Answer for Most in the Acute Setting!

Cangrelor Properties: PK, PD and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content